Company
L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.
We are an early-stage biotech company aiming to combat (emerging) viral infectious diseases with a high unmet medical need. With our proprietary technology, we are developing novel antiviral drugs that inhibit proteases and block viral replication.
Nijmegen, Gelderland, Netherlands
Send a message
Anglais
Anglais
Protinhi Therapeutics develops novel drugs acting as protease inhibitors to treat a wide range of illnesses. Currently we focus on viral infectious diseases, including Flaviviridae (e.g., dengue), Chikungunya and Corona virus. Our aim is to make those drugs available as new medication for patients in need of effective treatment.
In viral infectious diseases, protease encoded by virus plays a crutial role in its viral replication after infection of host cells. Protinhi’s innovative...
Protinhi Therapeutics develops novel drugs acting as protease inhibitors to treat a wide range of illnesses. Currently we focus on viral infectious diseases, including Flaviviridae (e.g., dengue), Chikungunya and Corona virus. Our aim is to make those drugs available as new medication for patients in need of effective treatment.
In viral infectious diseases, protease encoded by virus plays a crutial role in its viral replication after infection of host cells. Protinhi’s innovative compounds are inhibitory small molecules which block the protease, and consequentially also the mediated viral replication. The ability to block viral replication empowers our small molecules to be drug candidates not only for therapeutic treatment but also for prophylactic use.